Smartphone urinalysis firm raises $18 million in funding round

Smartphone urinalysis company has raised $18 million in series B funding to help develop its kidney testing service.’s kidney testing service has been assessed with Geisinger Health in conjunction with the US National Kidney Foundation, achieving a 71% adherence rate amongst patients with hypertension who have never been tested before. This improvement has the potential to help millions of at-risk patients – as demonstrated in the UK, where the service was rolled out in conjunction with the National Health Service. 10% of patients who took the test there tested positive for elevated levels of protein, indicating a previously unknown kidney disease. Identifying unknown kidney disease in patients creates an opportunity to reduce the elevated risk of complications, with significant cost savings potential.

Yonatan Adiri, founder and CEO, said: “We are reinventing existing paradigms of prevention. Instead of spending money and other resources to get people to come to the lab, we offer providers a full home-based service. With our ‘pay per protein’ model, we only get paid based on tangible cost improvements we deliver by detecting elevated protein in urine – which identifies previously undetected Chronic Kidney Disease.”

The funding round follows a number of significant milestones for over the past year, including FDA clearance, a global partnership with Siemens Healthineers and the launch of a consumer-focused UTI testing service in partnership with Boots UK.

The funding round was led by Aleph, with significant contributions from Samsung NEXT and private investors. The funds will be used to scale operations in the US and to continue the service’s rollout in the UK.

Michael Eisenberg, partner at Aleph, said: “We are thrilled to partner with Yonatan and the team. We are inspired by the company’s mission to prevent kidney disease complications, improve ease and quality of care, and ultimately, save lives. We believe that will dramatically reduce the cost of healthcare while increasing quality disease prevention.”

Its ‘medical selfie’ which involves urinalysis with the help of a smartphone provides a service in which testing can be conducted at home by using a smartphone camera to scan a dipstick. Results are sent directly to doctors and integrated with existing medical records.’s digital urinalysis pathway is already being used by over 100,000 patients via strategic partnerships throughout Europe and Israel.

Dr Joe Coresh, professor of Epidemiology, Medicine and Biostatics at Johns Hopkins University said: “We know that most patients with kidney disease and protein in their urine are untested and therefore go undiagnosed.’s user-friendly smartphone technology – directly connecting patients at home with the medical system – is a gamechanger addressing a big need. has demonstrated that it can deliver real improvements in line with best clinical practices and high patient satisfaction.”

'Smartphone urinalysis firm raises $18 million in funding round' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2019 Rapid Life Sciences Ltd, a Rapid News Group Company. All Rights Reserved.

Privacy policy

Terms and conditions